The announcement of an acquisition comes as no surprise given that potential strategic acquisitions are part of the group’s strategy in order to expand globally. We continue to favour Ergomed’s integrated business model of services provision and co-development, as it provides low-risk exposure to ongoing drug development programmes. However, the proposed acquisition adds a development segment to the business, increasing its overall risk profile. Ideally we would have preferred the acquisition to ....